CJC-1295 No DAC (GRF 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH) that is being investigated in laboratory and preclinical studies due to its capacity to induce pulsatile growth hormone (GH) secretion by the pituitary gland. Having a very short half-life of about 30 minutes, it is being explored as capable of replicating the natural GH rhythms without stimulating the receptor over a long period.

Critical disclaimer: CJC-1295 No DAC is a research peptide that has only been used in in vivo and in vitro as well as controlled preclinical models of laboratory research. The FDA, EMA, MHRA, and any other regulatory authority have not approved it to be used by humans in therapeutic form, as a self-administered drug, or as a treatment. The data provided in this blog is solely based on published research and protocol guidelines to use in educational and scientific purposes. It is not medical advice, and its misuse outside a research setting may be dangerous to health.

 Administration Route in Research Studies

In research studies and preclinical protocols, the subcutaneous (subQ) injection is always the preferred method of CJC-1295 No DAC. Subcutaneous injection introduces the peptide into the fatty layer under the skin, and the peptide is absorbed slowly into the bloodstream, and it resembles physiological delivery.

Key Studies Confirm this Route:

  • In a phase 1 clinical trial (Teichman et al., 2006), CJC-1295 was shown to increase GH (2- to 10-fold, 6+ days) and IGF-1 (1.5- to 3-fold, 9-11 days) dose-dependently upon subcutaneous injection in healthy adults (a half-life of 5.8-8.1 days). In 10-16%, it was reported to induce mild injection-site reactions.
  • Subcutaneous injections were used in preclinical studies of GHRH knockout mice to normalize body composition and growth (Alba et al., 2006).
  • No significant studies are comparing subcutaneous to intramuscular or other routes of CJC-1295 No DAC, but the few that mention intramuscular routes are not favored because of the faster absorption, which can ruin the intended pulsatile profile.

Preferred Injection Sites in Research Protocols

The most appropriate subcutaneous areas suggested by research guidelines to achieve regular absorption and minimum amount of discomfort include:

1. Abdomen (most common):

There is a lot of subcutaneous fat around the belly button (never in the midline) and it is evenly distributed around the belly button. It is the location of choice in the majority of human studies and animal studies because it is easily accessible and has low vessel/nerve density.

2. Thighs (outer/front): 

Access is easy and in long-term research, such a position is often turned to avoid local irritation.

3. Upper arms (back of the arm): 

The only good place, when there is no abdominal or thigh.

4. Rotation is necessary:

Rotate sites in sequence (e.g. left abdomen to right abdomen, left thigh to right thigh) to minimize the chances of lipohypertrophy (fat buildup), redness or localized swelling.

Research protocols technique notes:

  • Fine-gauge insulin syringe (27-31G, 0.5-1 inch).
  • Pinch a skinfold and insert at 45-90 degrees angle.
  • Subcutaneous injections do not require any aspiration.
  • Quickly inject; leave the needle in the patient a couple of seconds and then take it out.
  • Wipe with alcohol swabs the site and vial stopper.
  • Take on an empty stomach (fasting 2h or more) and usually at bedtime to coincide with natural nocturnal GH pulses.

Advantages and Disadvantages of each Injection Site.

1. Abdomen

Pros :

  • The greatest surface area that has soft fat beneath the skin means the greatest consistency of absorption.
  • Easy to access and visualize
  • Minimum density of major nerves and blood vessels, this means that there is less likelihood of bumping into anything.
  • Favorite in the majority of pharmacokinetic research due to good bioavailability.

Cons :

  • Visible site (this can be an issue with certain one)
  • Some chance of lipohypertrophy when used repeatedly at the same location.

2. Thighs (outer or front)

Pros :

  • A smooth layer of fat for absorption.
  • Painless self-administration when seated.
  • Less visible than the abdomen

Cons :

  • When there is more muscle below, the chances of intramuscular injection are higher when not pinched correctly.
  • May be hypersensitive/painful in some users.
  • Walking/movement can result in slight pain after the injection.

3. Upper Arms (back of the arm)

Pros :

  • Discreet and less visible
  • The fat layer is good in most individuals.

Cons :

  • More difficult to access and squeeze individually (requires help usually)
  • Slimmer fat in certain people, therefore, risk of intramuscular injection.
  • Underresearched in peptide experiments (less amount of data on consistency).

No single site is found in the research to be the best, although the abdomen is mentioned as the most reliable site; any of the three is usable with good technique and rotation.

Comparison of the pain level and speed of absorption.

Pain Level (subjective, on peptide research reports and studies of injection technique):

Abdomen: Lowest pain (1-3/10) because the thick fat layer cushions the needle, and also, this site has a low density of nerves.

Thighs: Moderate pain (3-6/10) due to a large number of nerve endings, and can sting more if the muscle is struck accidentally.

Upper arms: Variable (2-7/10) because some individuals have less fat, which makes it more uncomfortable. Furthermore, it also hurts when the angle is more acute.

Absorption Speed (in accordance with general subcutaneous pharmacokinetics; there is no direct comparison of the CJC-1295 site):

Abdomen: Moderate absorption (maximal plasma concentration 30 to 60 minutes after injection). It is most consistent because the blood flow is constant and the fat layer is stable.

Thighs: A little slower absorption and a larger fat depot have been found to slow the onset by 10 to 20 minutes in some studies.

Upper arms: In most case,s the same as the abdomen, but more alternating by the propinquity of muscles, and the thickness of the fat.

Clinically significant differences in GH/IGF-1 response across sites have not been found with the correct subQ technique (e.g., Teichman et al., 2006). Consistency is achieved through proper depth and correct rotation. It is not dependent on the site choice.

Mistakes to Avoid

There are some common mistakes that should be avoided including deep injection, poor aseptic technique, not pinching the skin, and continuous use of the same spot. Furthermore it is not recommended to be injected on an empty stomach because in models it has shown blunt GH response.

Disclaimer   

This blog is for educational and research purposes only, summarizing published studies on CJC-1295 No DAC. The peptide is  investigational  and  not approved  for human use outside controlled research. All discussions of injection sites and administration are for laboratory or preclinical contexts and should not be applied to humans. Misuse can lead to serious health risks. Always follow institutional review board (IRB) guidelines, animal welfare regulations, and biosafety protocols. Consult qualified researchers or supervisors for any experimental use. The author and publisher disclaim liability for any misuse of this information.

 References

  • Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295…   Journal of Clinical Endocrinology & Metabolism  . DOI: 10.1210/jc.2005-1536.  
  • Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295…   Journal of Clinical Endocrinology & Metabolism  . DOI: 10.1210/jc.2006-1702.  
  • Alba M, et al. (2006). Once-daily administration of CJC-1295… normalizes growth in the GHRH knockout mouse.   American Journal of Physiology-Endocrinology and Metabolism  . DOI: 10.1152/ajpendo.00201.2006.  
  • Peptide Dosages Protocol (2023). CJC-1295 No DAC 5mg Vial Dosage Protocol.  
  • Recess RX (2024). CJC-1295 Administration Guidelines.